The company's product pipeline includes PCLX-001, a small molecule, first-in-class N-myristoyl transferase (NMT) inhibitor that selectively kills cancer cells and eliminates tumors in animal models. The drug exploits a previously-unknown therapeutic target in cancer, making it a first-in-kind therapy. The diagnostic technology identifies those patients who will benefit from the drug, sparing many patients needless treatment. Pacylex Pharmaceuticals is a clinical stage company developing a first-in-class, daily, oral cancer therapy with a novel, broad, mechanism of action, as a refractory cancer monotherapy and potential future combination therapy. PCLX-001 is currently in Phase 1 clinical trial and has an excellent bioavailability, half-life, and drug exposure with an acceptable safety profile to date when administered orally once daily to patients with relapsed advanced solid tumors or refractory B-cell lymphomas. Pacylex is planning to expand the clinical program to AML at MD Anderson this fall in a DoD-supported Phase 2 study, as well as start two Phase 2 studies in DLBCL and solid tumor patients.